Literature DB >> 11012976

HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT.

J M González1, K Peter, F Esposito, I Nebié, J M Tiercy, A Bonelo, M Arévalo-Herrera, D Valmori, P Romero, S Herrera, G Corradin, J A López.   

Abstract

The role of antigen specific CD8+ T-lymphocytes in mediating protection against sporozoite-induced malaria has been well established in murine models. In humans, indirect evidence has accumulated suggesting a similar protective role for antigen-specific CD8+ T-lymphocytes. Nevertheless, the low frequency of circulating specific cells together with the lack of sensitive methods to quantify them has hampered the direct assessment of their function. Using a combination of short-term cell culture and IFN-gamma ELISPOT, we studied CD8+ T-lymphocyte responses to a panel of HLA-A*0201 binding peptides. In addition to confirming the response to already described epitopes, we also identified five new CD8+ T-lymphocyte epitopes. These epitopes are presented in pre-erythrocytic stages gene products of Plasmodium falciparum 7G8 strain and correspond to the following protein segments: circumsporozoite (CS) 64-72, 104-113, 299-308 and 403-411; liver stage antigen (LSA-1) repeat region; sporozoite surface protein 2 or thrombospondin related anonymous protein (SSP2/TRAP) 78-88 and 504-513. Four of these peptides are conserved amongst all published sequences of P. falciparum strains. We conclude that the modified IFN-gamma ELISPOT assay is a sensitive technique to monitor antigen-specific CD8+ T-lymphocyte responses in human malaria which may help in the improvement and assessment of the efficacy of malaria subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012976     DOI: 10.1046/j.1365-3024.2000.00331.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  16 in total

1.  HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.

Authors:  Kirsten E Lyke; Robin B Burges; Yacouba Cissoko; Lansana Sangare; Abdoulaye Kone; Modibo Dao; Issa Diarra; Marcelo A Fernández-Vina; Christopher V Plowe; Ogobara K Doumbo; Marcelo B Sztein
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum.

Authors:  Collette J Hillier; Lisa A Ware; Arnoldo Barbosa; Evelina Angov; Jeffrey A Lyon; D Gray Heppner; David E Lanar
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

3.  Plasma concentration of malaria parasite-derived macrophage migration inhibitory factor in uncomplicated malaria patients correlates with parasitemia and disease severity.

Authors:  Cong Han; Yahui Lin; Guangliang Shan; Zaixing Zhang; Xiaodong Sun; Zhensheng Wang; Chunyan Wei; Yan Deng; Lianhui Zhang; Lingyi Bu; Dingding Shao; Heng Wang
Journal:  Clin Vaccine Immunol       Date:  2010-08-11

4.  Sequence variation in the T-cell epitopes of the Plasmodium falciparum circumsporozoite protein among field isolates is temporally stable: a 5-year longitudinal study in southern Vietnam.

Authors:  Amadu Jalloh; Huynh van Thien; Marcelo U Ferreira; Jun Ohashi; Hiroyuki Matsuoka; Toshio Kanbe; Akihiko Kikuchi; Fumihiko Kawamoto
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

5.  Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria.

Authors:  Chandy C John; Ann M Moormann; Peter O Sumba; Ayub V Ofulla; Daniel C Pregibon; James W Kazura
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

6.  Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains.

Authors:  O G Gómez-Duarte; M F Pasetti; A Santiago; M B Sztein; S L Hoffman; M M Levine
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Increased CD4+/CD8+ double-positive T cells in chronic Chagasic patients.

Authors:  Nicolas A Giraldo; Natalia I Bolaños; Adriana Cuellar; Fanny Guzman; Ana Maria Uribe; Astrid Bedoya; Natalia Olaya; Zulma M Cucunubá; Nubia Roa; Fernando Rosas; Víctor Velasco; Concepción J Puerta; John M González
Journal:  PLoS Negl Trop Dis       Date:  2011-08-23

8.  Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.

Authors:  Daniel Dodoo; Michael R Hollingdale; Dorothy Anum; Kwadwo A Koram; Ben Gyan; Bartholomew D Akanmori; Josephine Ocran; Susan Adu-Amankwah; Harini Geneshan; Esteban Abot; Jennylyn Legano; Glenna Banania; Renato Sayo; Donald Brambilla; Sanjai Kumar; Denise L Doolan; William O Rogers; Judith Epstein; Thomas L Richie; Martha Sedegah
Journal:  Malar J       Date:  2011-06-20       Impact factor: 2.979

9.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

10.  Genetic diversity of vaccine candidate antigens in Plasmodium falciparum isolates from the Amazon basin of Peru.

Authors:  Stella M Chenet; Oralee H Branch; Ananias A Escalante; Carmen M Lucas; David J Bacon
Journal:  Malar J       Date:  2008-05-27       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.